MMR status-guided immunotherapy provides favorable cost-effectiveness and quality-adjusted survival in dMMR/MSI-H endometrial cancer
MMR Testing Helps Identify High Value Treatment for Endometrial Cancer
This mini review examines the economic value of mismatch repair (MMR) status-guided immunotherapy for advanced and recurrent endometrial can…
Testing for mismatch repair status helps doctors identify which patients with advanced endometrial cancer may benefit most from specific imm…
Nab-paclitaxel, cisplatin, and pembrolizumab achieved pathologic complete response in a patient with small cell lung cancer
New Treatment Approach Shows Success for a Rare Type of Lung Cancer
This case report describes a 61-year-old man with high-grade thoracic malignancy who achieved a pathologic complete response and undetectabl…
A 61-year-old man with a rare lung cancer showed a complete response after receiving a specific mix of drugs and surgery.
Evaluating Chemoimmunotherapy versus Monotherapy for Advanced NSCLC Patients with High PD-L1 Expression
Adding Chemotherapy to Immune Therapy for Lung Cancer Shows Mixed Results
A meta-analysis of 3,252 patients reveals that adding chemotherapy to ICI monotherapy does not provide a consistent survival advantage.
New analysis suggests that adding chemotherapy to immunotherapy for certain lung cancers may not provide a consistent survival benefit over …
ICIs Boost pCR in Early Triple-Negative Breast Cancer
Immune drugs combined with chemotherapy improve results for triple-negative breast cancer
Adding immune checkpoint inhibitors to chemotherapy improves pathological complete response in early triple-negative breast cancer, with PD-…
Adding immune checkpoint inhibitors to chemotherapy significantly increases the chance of clearing cancer cells in triple-negative breast ca…
Platinum agents, PARP inhibitors, and immune checkpoint inhibitors increase pCR rates in early-stage TNBC
New data shows specific drug combinations improve triple-negative breast cancer outcomes
This network meta-analysis of 7,683 patients with early-stage triple-negative breast cancer (TNBC) evaluated various neoadjuvant treatment r…
New data shows that adding specific drugs like pembrolizumab or bevacizumab to standard chemotherapy can improve response rates for early-st…
Immune checkpoint inhibitors increase risk of myocarditis and other cardiac toxicities in patients
Immune checkpoint inhibitors linked to increased risk of heart issues
This systematic review and network meta-analysis of 135 RCTs indicates that both PD-1/PD-L1 monotherapies and combination therapies increase…
Certain cancer treatments called immune checkpoint inhibitors are linked to a higher risk of heart inflammation and other serious cardiac pr…
ICI-based combinations show measurable but heterogeneous activity in platinum-resistant ovarian cancer
Combination therapy shows mixed results for advanced ovarian cancer
This systematic review and meta-analysis of ICI-based combination therapies in platinum-resistant ovarian cancer found an ORR of 21.9% and a…
New data reveals that while some patients with resistant ovarian cancer see stable disease, the effectiveness of certain drug combinations v…
mRNA vaccines reshape tumor microenvironment and induce durable anti-tumor immunity in lung cancer
mRNA Vaccines Show Promise for Lung Cancer Treatment
This systematic review examines the current status and prospects of mRNA vaccines for lung cancer. The authors synthesize evidence that mRNA…
New research explores how mRNA technology can reshape the tumor environment and trigger immune responses to fight lung cancer.
Dabrafenib and trametinib produce rapid response in a single case of BRAF V600E-mutant PHC
Targeted Treatment Shows Promise for Rare Pancreatic Cancer Type
This systematic review and case report analyze pancreatic hepatoid carcinoma (PHC) and the role of targeted therapies. The analysis identifi…
A specific drug combination showed a rapid and deep response in a patient with a rare type of pancreatic cancer involving a BRAF mutation.
Pembrolizumab plus chemotherapy improves ORR and OS in HER2-negative advanced gastric or gastroesophageal junction cancer
Pembrolizumab Plus Chemotherapy Improves Outcomes for Advanced Gastric Cancer
This systematic review and meta-analysis of 3406 patients found that pembrolizumab combined with chemotherapy significantly improved objecti…
Adding the drug pembrolizumab to chemotherapy shows promise in improving survival and response rates for patients with advanced gastric canc…
Combination of PD-1/PD-L1 inhibitors and chemotherapy shows no overall survival benefit in mCRPC
Combination therapy shows mixed results for advanced prostate cancer
This meta-analysis evaluated the addition of PD-1 or PD-L1 inhibitors to chemotherapy for patients with metastatic castration-resistant pros…
Adding immunotherapy to chemotherapy for advanced prostate cancer may not improve survival for all patients and can lead to more severe side…
Lenvatinib plus pembrolizumab did not improve overall survival compared to standard of care
Trial shows lenvatinib and pembrolizumab do not improve survival
This Phase 2 randomized trial evaluated lenvatinib and pembrolizumab in 374 adults with recurrent or metastatic head and neck squamous cell …
A Phase 2 trial found that a combination of lenvatinib and pembrolizumab did not improve overall survival for patients with advanced head an…